{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:36:44Z","timestamp":1790419004908,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.atherosclerosis.2009.12.009","type":"journal-article","created":{"date-parts":[[2009,12,12]],"date-time":"2009-12-12T09:17:59Z","timestamp":1260609479000},"page":"202-208","source":"Crossref","is-referenced-by-count":48,"title":["Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia"],"prefix":"10.1016","volume":"210","author":[{"given":"Leiv","family":"Ose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragos","family":"Budinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Hounslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Arneson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib1","unstructured":"Cardiovascular diseases, <http:\/\/www.who.int\/cardiovascular_diseases\/en\/>; 2009."},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib3","unstructured":"Joint Formulary Committee. British National Formulary. 57th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, http:\/\/www.bnf.org.uk\/bnf\/bnf\/current\/33422.htm; 2009 [accessed 30 06 09]."},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib4","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalised rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/oxfordjournals.eurheartj.a062547","article-title":"The recognition and management of hyperlipidaemia in adults: a policy statement of the European Atherosclerosis Society","volume":"9","year":"1988","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib6","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0002-9149(03)00474-0","article-title":"Effectiveness of statin titration on low density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events","volume":"92","author":"Foley","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.atherosclerosis.2008.03.016","article-title":"Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice","volume":"202","author":"Phatak","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib9","first-page":"904","article-title":"Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase","volume":"47","author":"Aoki","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5551\/jat1994.7.138","article-title":"Relative induction of mRNA for HMG-CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells","volume":"7","author":"Morikawa","year":"2000","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2009.12.009_bib11","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1016\/S1567-5688(09)70926-2","article-title":"Efficacy of pitavastatin and comparable safety to pravastatin","volume":"10","author":"Stender","year":"2009","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.atherosclerosis.2008.02.008","volume":"201","author":"Yokote","year":"2008","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2009.12.009_bib13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2217\/clp.09.20","article-title":"Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia","volume":"4","author":"Budinski","year":"2009","journal-title":"Clin Lipidol"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2009.12.009_bib14","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1185\/03007990903290886","article-title":"Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia","volume":"25","author":"Budinski","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib15","first-page":"599","article-title":"Interaction of oxidised low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants","volume":"34","author":"Aviram","year":"1996","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0163-7258(96)00202-1","article-title":"Low density lipoprotein and oxidised low density lipoprotein: their role in the development of atherosclerosis","volume":"74","author":"Hamilton","year":"1997","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/187152507781058672","article-title":"Statins and metabolism of high density lipoprotein","volume":"5","author":"Sviridov","year":"2007","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib18","doi-asserted-by":"crossref","first-page":"61C","DOI":"10.1016\/j.amjcard.2005.12.011","article-title":"Statin safety: an assessment using an administrative claims database","volume":"97","author":"Cziraky","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib19","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1086-5802(16)31104-4","article-title":"HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles","volume":"40","author":"Beaird","year":"2000","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib20","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1517\/14656566.8.14.2315","article-title":"Pitavastatin: efficacy and safety in intensive lipid-lowering","volume":"8","author":"Hayashi","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1365-2125.2005.02462.x","article-title":"Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin","volume":"60","author":"Ando","year":"2005","journal-title":"Br J Clin Pharmacol"},{"issue":"Abstract suppl.","key":"10.1016\/j.atherosclerosis.2009.12.009_bib22","first-page":"958","article-title":"Pitavastatin is not subject to clinically relevant pharmacokinetic interactions when administered with CYP3A4 inhibitors in healthy volunteers","volume":"30","author":"Nakagawa","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib23","unstructured":"Lipitor Summary of Product Characteristics http:\/\/emc.medicines.org.uk\/medicine\/1424\/SPC\/Lipitor+10mg%2c+20mg%2c+40mg%2c+80mg+Tablets\/>; 2009."},{"key":"10.1016\/j.atherosclerosis.2009.12.009_bib24","first-page":"709","article-title":"A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO Tablet)","volume":"36","author":"Kurihara","year":"2008","journal-title":"Jpn Pharmacol Ther"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191500901017X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191500901017X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:59:50Z","timestamp":1558702790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191500901017X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S002191500901017X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.12.009","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}